| 15.53 -1.22 (-7.28%) | 01-09 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 19.1 |
1-year : | 21.58 |
| Resists | First : | 16.35 |
Second : | 18.47 |
| Pivot price | 16.51 |
|||
| Supports | First : | 12.93 |
Second : | 10.75 |
| MAs | MA(5) : | 16.18 |
MA(20) : | 16.26  |
| MA(100) : | 13.18 |
MA(250) : | 9.04 |
|
| MACD | MACD : | 0.3 |
Signal : | 0.5 |
| %K %D | K(14,3) : | 38.3 |
D(3) : | 45.2 |
| RSI | RSI(14): 48.6 |
|||
| 52-week | High : | 18.47 | Low : | 3.09 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ PRE ] has closed above bottom band by 17.0%. Bollinger Bands are 24.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 16.97 - 17.06 | 17.06 - 17.11 |
| Low: | 15.1 - 15.21 | 15.21 - 15.27 |
| Close: | 15.38 - 15.54 | 15.54 - 15.64 |
Prenetics Global Limited, an investment holding company, operates as a diagnostics and genetic testing company. Its products include CircleDNA, a consumer genetic testing product; and Circle HealthPod, a rapid detection health monitoring system that allows users to take COVID-19 tests at point-of-care or at home utilizing the nucleic acid amplification test. The company's products also comprise ColoClear, a non-invasive FIT-DNA colorectal cancer screening test; Circle SnapShot, an off-the-shelf at-home blood test; Circle Medical, a diagnostic testing product; and Circle One and F1x/Fem. Prenetics Global Limited was founded in 2014 and is headquartered in Quarry Bay, Hong Kong.
Tue, 06 Jan 2026
All you need to know about Prenetics Global (PRE) rating upgrade to buy - MSN
Tue, 06 Jan 2026
Prenetics Sells Europa 3PL Unit to Sharpen Focus on High-Growth IM8 Brand - TipRanks
Tue, 06 Jan 2026
Health company sheds logistics arm to double down on fast-growing IM8 brand - Stock Titan
Tue, 06 Jan 2026
Prenetics Reinforces Strategic Focus on IM8, Divests Europa Business For Up to $13 Million - GlobeNewswire
Mon, 05 Jan 2026
Prenetics Provides Update on Voluntary Warrant Exchange Program, Reaching 86.7% Participation - mx.advfn.com
Tue, 30 Dec 2025
Prenetics halts Bitcoin purchases to focus on consumer health brand, IM8 - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 15 (M) |
| Shares Float | 11 (M) |
| Held by Insiders | 18.1 (%) |
| Held by Institutions | 10.3 (%) |
| Shares Short | 62 (K) |
| Shares Short P.Month | 156 (K) |
| EPS | -3.59 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 11.6 |
| Profit Margin | -60.4 % |
| Operating Margin | -26.2 % |
| Return on Assets (ttm) | -14.8 % |
| Return on Equity (ttm) | -30.1 % |
| Qtrly Rev. Growth | 202.8 % |
| Gross Profit (p.s.) | 2.34 |
| Sales Per Share | 5.05 |
| EBITDA (p.s.) | -3.19 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -4.33 |
| PEG Ratio | 0 |
| Price to Book value | 1.33 |
| Price to Sales | 3.07 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|